Cited by 312Alzheimer's disease research and treatmentsNeuroscience and Neuropharmacology ResearchDementia and Cognitive Impairment Research

Fyn kinase induces synaptic and cognitive impairments in a transgenic mouse model of Alzheimer’s disease

Open access
Chin, Jeannie, Palop, Jorge J., Puoliväli, Jukka, Massaro, Catherine, Bien-Ly, Nga, Gerstein, Hilary, Scearce-Levie, Kimberly, Masliah, Eliezer +1 more·2005·The Journal of Neuroscience

Abstract

Human amyloid precursor protein (hAPP) transgenic mice with high levels of amyloid-beta (Abeta) develop behavioral deficits that correlate with the depletion of synaptic activity-related proteins in the dentate gyrus. The tyrosine kinase Fyn is altered in Alzheimer's disease brains and modulates premature mortality and synaptotoxicity in hAPP mice. To determine whether Fyn also modulates Abeta-induced behavioral deficits and depletions of synaptic activity-dependent proteins, we overexpressed Fyn in neurons of hAPP mice with moderate levels of Abeta production. Compared with nontransgenic controls and singly transgenic mice expressing hAPP or FYN alone, doubly transgenic FYN/hAPP mice had striking depletions of calbindin, Fos, and phosphorylated ERK (extracellular signal-regulated kinase), impaired neuronal induction of Arc, and impaired spatial memory retention. These deficits were qualitatively and quantitatively similar to those otherwise seen only in hAPP mice with higher Abeta levels. Surprisingly, levels of active Fyn were lower in high expresser hAPP mice than in NTG controls and lower in FYN/hAPP mice than in FYN mice. Suppression of Fyn activity may result from dephosphorylation by striatal-enriched phosphatase, which was upregulated in FYN/hAPP mice and in hAPP mice with high levels of Abeta. Thus, increased Fyn expression is sufficient to trigger prominent neuronal deficits in the context of even relatively moderate Abeta levels, and inhibition of Fyn activity may help counteract Abeta-induced impairments.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1523/jneurosci.2980-05.2005

Cites

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The citation lists haven’t been fetched yet

References 69 · Cited by 312

Authors
Chin, J., Palop, J. J., Puoliväli, J., Massaro, C., Bien-Ly, N., Gerstein, H., Scearce-Levie, K., Masliah, E., & Mucke, L.
Affiliations
  • University of California, San Francisco (US)
  • Gladstone Institutes (US)
  • University of California San Diego (US)
Corresponding author
Mucke, Lennart
Venue
The Journal of Neuroscience
Published
2005-10-19
Volume
25
Issue
42
Pages
9694-9703
ISSN
  • 0270-6474 (ISSN-L)
  • 1529-2401
OpenAlex
W1982373527
Cited by
312
References
69
Citations by year
2026: 6 · 2025: 6 · 2024: 8 · 2023: 9 · 2022: 9 · 2021: 17 · 2020: 27 · 2019: 13 · 2018: 10 · 2017: 19 · 2016: 19 · 2015: 16 · 2014: 12 · 2013: 24 · 2012: 30
FWCI
6.59
Type
journal article
Language
en
Open access
Locations
  • Journal of Neuroscience (publishedVersion, cc-by-nc-sa)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • John Douglas French Alzheimer's Foundation
  • Academy of Finland
  • National Institutes of Health (AG‐022074)
  • National Institute on Aging (AG022074, P01AG022074)
  • National Institute of Neurological Disorders and Stroke (NS41787, R01NS041787)
Topics
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Keywords
Fyn, Alzheimer's disease, amyloid-beta, amyloid precursor protein transgenic mice, synaptic dysfunction, cognitive impairment, spatial memory, calbindin, FOS, ERK1/2 phosphorylation, Arc, dentate gyrus, synaptotoxicity
MeSH terms
Alzheimer Disease, Animals, Cognition Disorders, Disease Models, Animal, Female, Humans, Male, Mice, Inbred C57BL, Mice, Transgenic, Synapses, Amyloid beta-Protein Precursor, Proto-Oncogene Proteins c-fyn, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review